MCID: HPD002
MIFTS: 14

Hepadnavirus Infection

Categories: Rare diseases

Aliases & Classifications for Hepadnavirus Infection

MalaCards integrated aliases for Hepadnavirus Infection:

Name: Hepadnavirus Infection 49
Hepadnaviridae Infections 69

Classifications:



External Ids:

UMLS 69 C0206746

Summaries for Hepadnavirus Infection

MalaCards based summary : Hepadnavirus Infection, also known as hepadnaviridae infections, is related to hepatocellular carcinoma and hepatitis. An important gene associated with Hepadnavirus Infection is TP53 (Tumor Protein P53). The drugs Ritonavir and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include liver and t cells.

Related Diseases for Hepadnavirus Infection

Diseases related to Hepadnavirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 10.1
2 hepatitis 10.1
3 alpha-fetoprotein deficiency 10.0
4 hepatitis b 9.9
5 liver disease 9.9
6 t cell deficiency 9.9
7 viral hepatitis 9.9

Graphical network of the top 20 diseases related to Hepadnavirus Infection:



Diseases related to Hepadnavirus Infection

Symptoms & Phenotypes for Hepadnavirus Infection

Drugs & Therapeutics for Hepadnavirus Infection

Drugs for Hepadnavirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 294)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3 155213-67-5 392622
2
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
3
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
4
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Ribavirin Approved Phase 4,Phase 3,Phase 2,Not Applicable 36791-04-5 37542
7
rituximab Approved Phase 4,Phase 3,Not Applicable 174722-31-7 10201696
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
10
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
11
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
12
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
13
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
14
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 62304-98-7
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
16
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
17
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Not Applicable 215647-85-1, 99210-65-8
18
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
19
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Not Applicable 8008-53-5
20
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
21 Simethicone Approved Phase 4,Phase 3
22
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
23
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
24
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
25
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
26
Etravirine Approved Phase 4 269055-15-4 193962
27
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
28
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351
29
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
30
Lenograstim Approved, Investigational Phase 4 135968-09-1
31
Methadone Approved Phase 4 76-99-3 4095
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
34 Tocopherol Approved, Investigational, Nutraceutical Phase 4
35 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
36
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
38
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
39
Maleic acid Experimental Phase 4,Phase 1 110-16-7 444266
40 Adefovir Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41
Tenofovir Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
42 Chlorhexidine gluconate Phase 4
43 Clevudine Phase 4,Phase 3,Phase 2
44 Prednisolone acetate Phase 4,Phase 2,Not Applicable
45 Atorvastatin Calcium Phase 4 134523-03-8
46 Analgesics Phase 4,Phase 3
47 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 2,Not Applicable
49
protease inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
50 Methylprednisolone acetate Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1072)

# Name Status NCT ID Phase Drugs
1 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
2 Antiviral Efficacy of Switching to ETV Plus TDF Unknown status NCT01597934 Phase 4 Group A (Zeffix, Sebivo, Hepsera);Group B (Baraclude, Viread)
3 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
4 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
5 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
6 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
7 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
8 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
9 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
10 An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
11 EFFORT Extension Study Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
12 Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
13 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
14 3E Extension Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
15 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
16 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
17 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
18 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
19 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
20 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
21 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
22 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
23 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
24 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
25 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
26 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
27 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
28 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
29 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
30 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
31 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
32 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
33 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
34 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
35 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
36 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
37 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
38 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
39 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
40 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
41 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
42 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
43 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
44 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
45 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
46 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
47 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
48 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
49 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine
50 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon

Search NIH Clinical Center for Hepadnavirus Infection

Genetic Tests for Hepadnavirus Infection

Anatomical Context for Hepadnavirus Infection

MalaCards organs/tissues related to Hepadnavirus Infection:

38
Liver, T Cells

Publications for Hepadnavirus Infection

Articles related to Hepadnavirus Infection:

(show all 27)
# Title Authors Year
1
Animal Models and the Molecular Biology of Hepadnavirus Infection. ( 25833941 )
2015
2
Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. ( 25772035 )
2015
3
Serological and molecular evidence ofA hepadnavirus infection in swine. ( 25780820 )
2015
4
Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. ( 19193791 )
2009
5
Immune selection during chronic hepadnavirus infection. ( 19669275 )
2008
6
Rapid production of neutralizing antibody leads to transient hepadnavirus infection. ( 14722274 )
2004
7
Frequency of spontaneous mutations in an avian hepadnavirus infection. ( 11559794 )
2001
8
Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. ( 11584382 )
2001
9
Hepadnavirus infection in captive gibbons. ( 10684318 )
2000
10
Antisense oligonucleotide therapy of hepadnavirus infection. ( 10565037 )
2000
11
Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. ( 10775634 )
2000
12
Low dynamic state of viral competition in a chronic avian hepadnavirus infection. ( 10799602 )
2000
13
Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. ( 9419372 )
1998
14
Mouse genetics at work: a new model of chronic hepadnavirus infection. ( 9657123 )
1998
15
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. ( 9585237 )
1998
16
Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. ( 8986943 )
1997
17
Absence of mutations in the p53 tumor suppressor gene in woodchuck hepatocellular carcinomas associated with hepadnavirus infection and intake of aflatoxin B1. ( 9006107 )
1996
18
Therapy of hepadnavirus infection using antisense oligonucleotides. ( 8666519 )
1995
19
Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. ( 8230462 )
1993
20
A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. ( 1514437 )
1992
21
Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. ( 1893774 )
1991
22
X antigen/antibody markers in hepadnavirus infections. Antibodies to the X gene product(s). ( 2365196 )
1990
23
X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum. ( 2311861 )
1990
24
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: immunochemical analysis of woodchuck alpha-fetoprotein and measurement in serum by quantitative monoclonal radioimmunoassay. ( 1693355 )
1990
25
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: normal physiological patterns and responses to woodchuck hepatitis virus infection and hepatocellular carcinoma. ( 1701355 )
1990
26
Liver diseases associated with hepadnavirus infection. A study in duck model. ( 2620307 )
1989
27
Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. ( 3485201 )
1986

Variations for Hepadnavirus Infection

Expression for Hepadnavirus Infection

Search GEO for disease gene expression data for Hepadnavirus Infection.

Pathways for Hepadnavirus Infection

GO Terms for Hepadnavirus Infection

Sources for Hepadnavirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....